|
US7244827B2
(en)
|
2000-04-12 |
2007-07-17 |
Agensys, Inc. |
Nucleic acid and corresponding protein entitled 24P4C12 useful in treatment and detection of cancer
|
|
US6943235B1
(en)
*
|
1999-04-12 |
2005-09-13 |
Agensys, Inc. |
Transmembrane protein expressed in prostate cancer
|
|
US20050255106A1
(en)
*
|
1999-05-22 |
2005-11-17 |
Linda Diehl |
Induction of anti-tumor ctl immunity through in vivo triggering of 4-1bb and/or cd40
|
|
US20030059427A1
(en)
*
|
2000-04-28 |
2003-03-27 |
Force Walker R. |
Isolation and characterization of highly active anti-CD40 antibody
|
|
JP2004514423A
(ja)
|
2000-09-07 |
2004-05-20 |
シュライバー， ジョン アール． |
トランスジェニックｘｅｎｏｍｏｕｓｅ（登録商標）から獲得されるｐｅｕｄｏｍｏｎａｓａｅｒｕｇｉｎｏｓａｌｐｓに対するヒト抗体
|
|
PT1391464E
(pt)
|
2001-04-27 |
2007-11-15 |
Kirin Pharma Kk |
Anticorpo monoclonal anti-cd40
|
|
US7658924B2
(en)
|
2001-10-11 |
2010-02-09 |
Amgen Inc. |
Angiopoietin-2 specific binding agents
|
|
AR039067A1
(es)
*
|
2001-11-09 |
2005-02-09 |
Pfizer Prod Inc |
Anticuerpos para cd40
|
|
JP2005519586A
(ja)
|
2001-11-21 |
2005-07-07 |
セルテック アール アンド ディー， インコーポレイテッド |
Ｃｄ８３遺伝子産物を利用したサイトカイン・レベルの操作法
|
|
US20040185040A1
(en)
|
2001-11-21 |
2004-09-23 |
Celltech R & D Limited |
Modulating immune responses
|
|
MXPA04012116A
(es)
*
|
2002-06-07 |
2005-04-19 |
Zymogenetics Inc |
Uso del il-21 en cancer y otras aplicaciones terapeuticas.
|
|
US7052694B2
(en)
*
|
2002-07-16 |
2006-05-30 |
Mayo Foundation For Medical Education And Research |
Dendritic cell potentiation
|
|
HN2004000285A
(es)
|
2003-08-04 |
2006-04-27 |
Pfizer Prod Inc |
ANTICUERPOS DIRIGIDOS A c-MET
|
|
WO2005037235A2
(en)
*
|
2003-10-16 |
2005-04-28 |
Imclone Systems Incorporated |
Fibroblast growth factor receptor-1 inhibitors and methods of treatment thereof
|
|
US8277810B2
(en)
|
2003-11-04 |
2012-10-02 |
Novartis Vaccines & Diagnostics, Inc. |
Antagonist anti-CD40 antibodies
|
|
PT1694360E
(pt)
*
|
2003-11-04 |
2010-12-13 |
Novartis Vaccines & Diagnostic |
Utilização de anticorpos monoclonais antagonistas anti-cd40 para o tratamento de doenças auto-imunes e inflamatórias e da rejeição ao transplante de orgãos
|
|
EP1706425A2
(en)
|
2003-12-05 |
2006-10-04 |
John R. Schreiber |
Human anti-pseudomonas-aeruginosa antibodies derived from transgenic xenomouse®
|
|
US20050136055A1
(en)
*
|
2003-12-22 |
2005-06-23 |
Pfizer Inc |
CD40 antibody formulation and methods
|
|
BRPI0417266B8
(pt)
|
2003-12-25 |
2021-05-25 |
Kyowa Hakko Kirin Co Ltd |
anticorpo monoclonal, seu uso e composição farmacêutica
|
|
MX350383B
(es)
|
2004-01-09 |
2017-09-04 |
Pfizer |
Anticuerpos contra madcam.
|
|
AU2005227322A1
(en)
|
2004-03-23 |
2005-10-06 |
Biogen Idec Ma Inc. |
Receptor coupling agents and therapeutic uses thereof
|
|
US20060099203A1
(en)
|
2004-11-05 |
2006-05-11 |
Pease Larry R |
B7-DC binding antibody
|
|
EP1768999B1
(en)
*
|
2004-06-30 |
2013-06-19 |
Mayo Foundation For Medical Education And Research |
sHIgM12 antibody useful to treat multiple sclerosis
|
|
EP2287195B1
(en)
|
2004-07-01 |
2019-05-15 |
Novo Nordisk A/S |
Pan-kir2dl nk-receptor antibodies and their use in diagnostik and therapy
|
|
WO2006017574A1
(en)
*
|
2004-08-03 |
2006-02-16 |
Mayo Foundation For Medical Education And Research |
Improving treatments
|
|
US7563443B2
(en)
*
|
2004-09-17 |
2009-07-21 |
Domantis Limited |
Monovalent anti-CD40L antibody polypeptides and compositions thereof
|
|
CN101103043A
(zh)
|
2005-01-06 |
2008-01-09 |
诺和诺德公司 |
Kir结合剂和使用其的方法
|
|
JP4986633B2
(ja)
*
|
2005-01-12 |
2012-07-25 |
協和発酵キリン株式会社 |
安定化されたヒトＩｇＧ２およびＩｇＧ３抗体
|
|
EP2567976B1
(en)
*
|
2005-03-23 |
2017-07-19 |
Genmab A/S |
Antibodies against CD38 for treatment of multiple myeloma
|
|
CA2763671A1
(en)
|
2005-04-26 |
2006-11-02 |
Pfizer Inc. |
P-cadherin antibodies
|
|
WO2006125143A2
(en)
*
|
2005-05-18 |
2006-11-23 |
Novartis Ag |
Methods for diagnosis and treatment of proliferative disorders mediated by cd40 signaling
|
|
WO2006125117A2
(en)
*
|
2005-05-18 |
2006-11-23 |
Novartis Ag |
Methods for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component
|
|
GB0512225D0
(en)
*
|
2005-06-16 |
2005-07-27 |
Univ Sheffield |
Immunoglobulin molecules
|
|
HUE035853T2
(en)
|
2005-07-18 |
2018-05-28 |
Seattle Genetics Inc |
Beta-glucuronide-linker-drug conjugates
|
|
CA2621371C
(en)
|
2005-09-07 |
2018-05-15 |
Amgen Fremont Inc. |
Human monoclonal antibodies to activin receptor-like kinase-1
|
|
WO2007103048A2
(en)
*
|
2006-03-01 |
2007-09-13 |
Regents Of The University Of Colorado |
Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity
|
|
WO2007130493A2
(en)
*
|
2006-05-03 |
2007-11-15 |
Regents Of The University Of Colorado |
Cd40 agonist antibody/type1 interferon synergistic adjuvant combination, conjugates containing and use thereof as a therapeutic to enhance cellular immunity
|
|
EA200802058A1
(ru)
|
2006-05-09 |
2009-06-30 |
Пфайзер Продактс Инк. |
Производные циклоалкиламинокислот и их фармацевтические композиции
|
|
EP1854810A1
(en)
*
|
2006-05-09 |
2007-11-14 |
PanGenetics B.V. |
Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody
|
|
CA2652148C
(en)
|
2006-05-12 |
2016-10-04 |
Fondazione Centro San Raffaele Del Monte Tabor |
Tolerogenic dendritic cells, method for their production and uses thereof
|
|
US20090074711A1
(en)
*
|
2006-09-07 |
2009-03-19 |
University Of Southhampton |
Human therapies using chimeric agonistic anti-human cd40 antibody
|
|
JP5632582B2
(ja)
*
|
2006-12-14 |
2014-11-26 |
中外製薬株式会社 |
抗Ｃｌａｕｄｉｎ３モノクローナル抗体およびそれを用いる癌の治療および診断
|
|
EP2426145B1
(en)
|
2007-02-23 |
2017-01-18 |
Merck Sharp & Dohme Corp. |
Engineered anti-il-23p19 antibodies
|
|
AR065420A1
(es)
*
|
2007-02-23 |
2009-06-03 |
Schering Corp |
Anticuerpos anti-il-23 p19 de ingenieria
|
|
CA2693053C
(en)
|
2007-05-30 |
2021-01-05 |
Xencor, Inc. |
Methods and compositions for inhibiting cd32b expressing cells
|
|
EP1997830A1
(en)
|
2007-06-01 |
2008-12-03 |
AIMM Therapeutics B.V. |
RSV specific binding molecules and means for producing them
|
|
US8039597B2
(en)
*
|
2007-09-07 |
2011-10-18 |
Agensys, Inc. |
Antibodies and related molecules that bind to 24P4C12 proteins
|
|
MX2010005080A
(es)
|
2007-11-07 |
2010-07-28 |
Genentech Inc |
Metodos y composiciones para determinar la sensibilidad de linfoma de celula b al tratamiento con anticuerpos anti-cd40.
|
|
DK2851374T3
(en)
|
2007-12-14 |
2017-06-19 |
Bristol Myers Squibb Co |
Binding molecules to the human OX40 receptor
|
|
JO2913B1
(en)
|
2008-02-20 |
2015-09-15 |
امجين إنك, |
Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
|
|
AU2010222928B2
(en)
*
|
2008-07-16 |
2012-11-29 |
Baylor Research Institute |
Antigen presenting cell targeted vaccines
|
|
ES2378513T3
(es)
|
2008-08-06 |
2012-04-13 |
Pfizer Inc. |
Compuestos 2-heterociclilamino piracinas sustituidas en posición 6 como inhibidores de CHK-1
|
|
CN102170908A
(zh)
*
|
2008-08-29 |
2011-08-31 |
莱顿大学医学中心附属莱顿教学医院 |
向个体的肿瘤引流淋巴结递送cd40激动剂
|
|
EP2198878A1
(en)
|
2008-12-18 |
2010-06-23 |
University Of Miami |
Polypeptide bombesin antagonists
|
|
AU2016244220B2
(en)
*
|
2008-12-23 |
2018-05-17 |
Amgen Inc. |
Human CGRP receptor binding proteins
|
|
JO3382B1
(ar)
*
|
2008-12-23 |
2019-03-13 |
Amgen Inc |
أجسام مضادة ترتبط مع مستقبل cgrp بشري
|
|
WO2010111018A1
(en)
*
|
2009-03-06 |
2010-09-30 |
Agensys, Inc. |
Antibody drug conjugates (adc) that bind to 24p4c12 proteins
|
|
EP2406289B1
(en)
|
2009-03-10 |
2017-02-22 |
Baylor Research Institute |
Antigen presenting cell targeted anti-viral vaccines
|
|
DK2406286T3
(en)
|
2009-03-10 |
2016-08-22 |
Baylor Res Inst |
Anti-cd40 antibodies and uses thereof
|
|
KR101787768B1
(ko)
|
2009-04-18 |
2017-10-18 |
제넨테크, 인크. |
항-ｃｄ４０ 항체를 사용한 치료에 대한 ｂ-세포 림프종의 반응성 평가를 위한 방법
|
|
CA2759146C
(en)
|
2009-04-20 |
2017-06-13 |
Kyowa Kirin Co., Ltd. |
Agonist anti-cd40 antibody
|
|
TW201138843A
(en)
|
2009-12-18 |
2011-11-16 |
Colgate Palmolive Co |
Biguanide preservation of precipitated calcium carbonate
|
|
WO2011083391A2
(en)
|
2010-01-05 |
2011-07-14 |
Pfizer Inc. |
Biomarkers for anti-igf-ir cancer therapy
|
|
BR112012024713B1
(pt)
|
2010-03-31 |
2021-02-17 |
Boehringer Ingelheim International Gmbh |
anticorpo humanizado, seus usos e composição farmacêutica que o compreende
|
|
GB201006096D0
(en)
*
|
2010-04-13 |
2010-05-26 |
Alligator Bioscience Ab |
Novel compositions and uses thereof
|
|
FR2959994B1
(fr)
*
|
2010-05-12 |
2012-08-24 |
Lfb Biotechnologies |
Nouveaux anticorps humanises 12g4 mutes et leurs fragments diriges contre le recepteur humain de l'hormone anti-mullerienne de type ii
|
|
PT2614082T
(pt)
|
2010-09-09 |
2018-12-03 |
Pfizer |
Moléculas de ligação a 4-1bb
|
|
WO2012041635A1
(en)
*
|
2010-09-29 |
2012-04-05 |
Universite De Liege |
Combination of an agonistic anti-cd40 monoclonal antibody or a cd40 ligand and inactivated or attenuated bacteria for use in the treatment and/or prevention of mastitis
|
|
AR083847A1
(es)
|
2010-11-15 |
2013-03-27 |
Novartis Ag |
Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
|
|
EP3974453A3
(en)
*
|
2010-11-16 |
2022-08-03 |
Amgen Inc. |
Agents and methods for treating diseases that correlate with bcma expression
|
|
KR101614997B1
(ko)
*
|
2011-01-10 |
2016-04-22 |
씨티 아틀란틱 엘티디. |
종양 관련 항원 결합 항체를 포함하는 조합 요법
|
|
GB201103578D0
(en)
|
2011-03-02 |
2011-04-13 |
Sabrepharm Ltd |
Dipyridinium derivatives
|
|
HUE065915T2
(hu)
|
2011-03-11 |
2024-06-28 |
Beth Israel Deaconess Medical Ct Inc |
Anti-CD40 antitestek és alkalmazásaik
|
|
DK2699598T3
(en)
|
2011-04-19 |
2019-04-23 |
Pfizer |
COMBINATIONS OF ANTI-4-1BB ANTIBODIES AND ADCC-INducing ANTIBODIES FOR TREATMENT OF CANCER
|
|
BR112013026828A2
(pt)
|
2011-04-21 |
2016-11-29 |
Bristol Myers Squibb Co |
polipeptídeos de anticorpo que antagonizam cd40
|
|
WO2012145746A1
(en)
*
|
2011-04-21 |
2012-10-26 |
The Regents Of The University Of Colorado, A Body Corporate |
Compositions and methods for the treatment of neuromyelitis optica
|
|
CN113461819B
(zh)
*
|
2011-04-29 |
2024-01-02 |
埃派斯进有限公司 |
抗-cd40抗体及其使用方法
|
|
WO2012158818A2
(en)
|
2011-05-16 |
2012-11-22 |
Fabion Pharmaceuticals, Inc. |
Multi-specific fab fusion proteins and methods of use
|
|
GB201115280D0
(en)
*
|
2011-09-05 |
2011-10-19 |
Alligator Bioscience Ab |
Antibodies, uses and methods
|
|
GB201116092D0
(en)
|
2011-09-16 |
2011-11-02 |
Bioceros B V |
Antibodies and uses thereof
|
|
SG11201400859SA
(en)
|
2011-09-22 |
2014-04-28 |
Amgen Inc |
Cd27l antigen binding proteins
|
|
SG10201603411WA
(en)
|
2011-10-28 |
2016-07-28 |
Teva Pharmaceuticals Australia Pty Ltd |
Polypeptide constructs and uses thereof
|
|
TWI679212B
(zh)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對ｂｃｍａ之e3以及ｃｄ３的結合分子
|
|
WO2013091661A2
(en)
*
|
2011-12-23 |
2013-06-27 |
Aarhus Universitet |
Proteolytic resistant protein affinity tag
|
|
EP3453723B1
(en)
|
2012-01-31 |
2021-08-11 |
Regeneron Pharmaceuticals, Inc. |
Anti-asic1 antibodies and uses thereof
|
|
AR090263A1
(es)
*
|
2012-03-08 |
2014-10-29 |
Hoffmann La Roche |
Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
|
|
US20150064203A1
(en)
*
|
2012-03-08 |
2015-03-05 |
Japan Science And Technology Agency |
Anticancer agent
|
|
US20140004131A1
(en)
|
2012-05-04 |
2014-01-02 |
Novartis Ag |
Antibody formulation
|
|
AU2013255511B2
(en)
|
2012-05-04 |
2016-01-28 |
Pfizer Inc. |
Prostate-associated antigens and vaccine-based immunotherapy regimens
|
|
ES2873877T3
(es)
|
2012-06-18 |
2021-11-04 |
Ospedale San Raffaele Srl |
Composiciones y métodos para disminuir una respuesta inmune
|
|
AU2013337903B2
(en)
*
|
2012-10-30 |
2018-08-16 |
Apexigen, Inc. |
Anti-CD40 antibodies and methods of use
|
|
UY35148A
(es)
|
2012-11-21 |
2014-05-30 |
Amgen Inc |
Immunoglobulinas heterodiméricas
|
|
US9840559B2
(en)
|
2013-02-01 |
2017-12-12 |
The Regents Of The University Of California |
Anti-CD83 antibodies and use thereof
|
|
WO2014144817A2
(en)
|
2013-03-15 |
2014-09-18 |
Amgen Inc. |
Inhibitory polypeptides specific to wnt inhibitors
|
|
SMT201800503T1
(it)
|
2013-03-18 |
2018-11-09 |
Janssen Pharmaceuticals Inc |
Anticorpi anti-cd (ox40) umanizzati e loro usi
|
|
ES2774976T3
(es)
|
2013-04-29 |
2020-07-23 |
Teva Pharmaceuticals Australia Pty Ltd |
Anticuerpos anti-CD38 y fusiones con interferón alfa-2b atenuado
|
|
US11117975B2
(en)
|
2013-04-29 |
2021-09-14 |
Teva Pharmaceuticals Australia Pty Ltd |
Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
|
|
RU2671558C2
(ru)
|
2013-06-14 |
2018-11-02 |
Псайоксус Терапьютикс Лимитед |
Режим введения и составы для аденовирусов типа в
|
|
WO2014202552A1
(en)
|
2013-06-17 |
2014-12-24 |
Koninklijke Philips N.V. |
Magnetic resonance imaging subject support
|
|
GB201311487D0
(en)
*
|
2013-06-27 |
2013-08-14 |
Alligator Bioscience Ab |
Bispecific molecules
|
|
BR112016002614B8
(pt)
|
2013-08-08 |
2023-11-07 |
Hopitaux Paris Assist Publique |
Imunocitoquina e composição farmacêutica
|
|
EP3712166A1
(en)
|
2013-09-05 |
2020-09-23 |
Amgen Inc. |
Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
|
|
AR097584A1
(es)
|
2013-09-12 |
2016-03-23 |
Hoffmann La Roche |
Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
|
|
AU2014338864C1
(en)
|
2013-10-25 |
2020-07-16 |
Akamis Bio Limited |
Oncolytic adenoviruses armed with heterologous genes
|
|
GB201322583D0
(en)
*
|
2013-12-19 |
2014-02-05 |
Alligator Bioscience Ab |
Antibodies
|
|
KR20160085888A
(ko)
*
|
2013-12-20 |
2016-07-18 |
에프. 호프만-라 로슈 아게 |
항-ang2 항체 및 cd40 작용제를 사용한 조합 요법
|
|
JP7037884B2
(ja)
|
2014-01-13 |
2022-03-17 |
ベイラー リサーチ インスティテュート |
Ｈｐｖ及びｈｐｖ関連疾患に対する新規のワクチン
|
|
WO2015134988A1
(en)
|
2014-03-07 |
2015-09-11 |
Bristol-Myers Squibb Company |
Method of using antibody polypeptides that antagonize cd40 to treat ibd
|
|
RU2016142476A
(ru)
|
2014-03-31 |
2018-05-07 |
Дженентек, Инк. |
Комбинированная терапия, включающая антиангиогенезные агенты и агонисты, связывающие ох40
|
|
KR102632731B1
(ko)
*
|
2014-04-30 |
2024-02-01 |
막스-델부뤽-센트럼 퓌어 몰레쿨라레 메디친 인 데어 헬름홀츠-게마인샤프트 |
Ｃｄ269에 대한 인간화 항체
|
|
UA119352C2
(uk)
|
2014-05-01 |
2019-06-10 |
Тева Фармасьютикалз Острейліа Пті Лтд |
Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
|
|
US10156562B2
(en)
|
2014-05-16 |
2018-12-18 |
Amgen Inc. |
Assay for detecting Th1 and Th2 cell populations
|
|
GB201413665D0
(en)
|
2014-07-03 |
2014-09-17 |
Transimmune Ag And Yale University |
Method for obtaining globally activated monocytes
|
|
EP3180087B1
(en)
|
2014-08-12 |
2019-03-13 |
Alligator Bioscience AB |
Combination therapies with anti cd40 antibodies
|
|
EP3070102A1
(en)
|
2015-03-18 |
2016-09-21 |
F. Hoffmann-La Roche AG |
Combination therapy of antibodies human cd40 activating antibodies and anti human pld-1 antibodies
|
|
KR20170035945A
(ko)
*
|
2014-08-14 |
2017-03-31 |
에프. 호프만-라 로슈 아게 |
인간 cd40을 활성화시키는 항체 및 인간 pd-l1에 대한 항체의 병용 요법
|
|
WO2016044224A1
(en)
|
2014-09-15 |
2016-03-24 |
Amgen Inc. |
Bi-specific anti-cgrp receptor/pac1 receptor antigen binding proteins and uses thereof
|
|
WO2016061617A1
(en)
|
2014-10-23 |
2016-04-28 |
Dendrocyte Biotech Pty Ltd |
Cd83 binding proteins and uses thereof
|
|
US9815886B2
(en)
|
2014-10-28 |
2017-11-14 |
Adma Biologics, Inc. |
Compositions and methods for the treatment of immunodeficiency
|
|
CA2965414C
(en)
|
2014-10-29 |
2024-01-09 |
Teva Pharmaceuticals Australia Pty Ltd |
Interferon .alpha.2.beta. variants
|
|
CA2963720C
(en)
*
|
2014-10-29 |
2024-05-14 |
Seattle Genetics, Inc. |
Dosage and administration of non-fucosylated anti-cd40 antibodies
|
|
TWI595006B
(zh)
|
2014-12-09 |
2017-08-11 |
禮納特神經系統科學公司 |
抗ｐｄ－１抗體類和使用彼等之方法
|
|
BR112017020952A2
(pt)
|
2015-04-13 |
2018-07-10 |
Five Prime Therapeutics Inc |
método de tratamento de câncer, composição e uso da composição
|
|
TWI799849B
(zh)
|
2015-04-24 |
2023-04-21 |
美商安美基公司 |
治療或預防偏頭痛之方法
|
|
PE20180241A1
(es)
|
2015-04-30 |
2018-01-31 |
Psioxus Therapeutics Ltd |
Adenovirus oncolitico que codifica una proteina b7
|
|
MX391086B
(es)
|
2015-06-24 |
2025-03-21 |
Hoffmann La Roche |
Anticuerpos anti-receptor de transferrina con afinidad diseñada.
|
|
HK1252666A1
(zh)
*
|
2015-06-29 |
2019-05-31 |
Bristol-Myers Squibb Company |
针对cd40的抗体
|
|
AU2016285920A1
(en)
|
2015-06-29 |
2018-02-01 |
Bristol-Myers Squibb Company |
Antibodies to CD40 with enhanced agonist activity
|
|
IL274572B2
(en)
|
2015-07-16 |
2024-01-01 |
Biolinerx Ltd |
Compositions and methods for treating cancer
|
|
WO2017040932A1
(en)
|
2015-09-04 |
2017-03-09 |
Primatope Therapeutics Inc. |
Humanized anti-cd40 antibodies and uses thereof
|
|
CR20180177A
(es)
|
2015-09-30 |
2018-06-22 |
Janssen Biotech Inc |
Anticuerpos agonistas que se unen específicamente a cd40 humana y método de uso
|
|
AR106189A1
(es)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
|
|
NZ741067A
(en)
|
2015-10-02 |
2023-07-28 |
Hoffmann La Roche |
Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
|
|
GB2543550A
(en)
|
2015-10-21 |
2017-04-26 |
Hox Therapeutics Ltd |
Peptides
|
|
EP3370768B9
(en)
|
2015-11-03 |
2022-03-16 |
Janssen Biotech, Inc. |
Antibodies specifically binding pd-1 and their uses
|
|
CN108699120B
(zh)
*
|
2015-11-16 |
2022-05-13 |
Ubi蛋白公司 |
用于延长蛋白质半衰期的方法
|
|
EP3386536A4
(en)
*
|
2015-12-07 |
2019-07-31 |
Opi Vi- IP Holdco LLC |
COMPOSITION OF ANTIBODY CONSTRUCT AGONIST CONJUGATES AND METHOD FOR USE THEREOF
|
|
EA201891022A1
(ru)
|
2015-12-17 |
2019-01-31 |
Псайоксус Терапьютикс Лимитед |
Вирус, кодирующий антитело к комплексу tcr или фрагмент указанного антитела
|
|
ES2985566T3
(es)
|
2016-03-04 |
2024-11-06 |
Univ Rockefeller |
Anticuerpos contra CD40 con actividad agonista mejorada
|
|
PL3426271T3
(pl)
|
2016-03-10 |
2025-11-24 |
Cg Oncology, Inc. |
Sposoby leczenia guzów litych terapią skojarzoną
|
|
CN109476756B
(zh)
|
2016-03-15 |
2022-05-31 |
埃泰美德(香港)有限公司 |
一种多特异性Fab融合蛋白及其用途
|
|
CN109069638B
(zh)
|
2016-03-24 |
2022-03-29 |
璟尚生物制药公司 |
用于癌症治疗的三特异性抑制剂
|
|
KR20180134351A
(ko)
|
2016-03-25 |
2018-12-18 |
시애틀 지네틱스, 인크. |
페길화된 약물-링커 및 그의 중간체의 제조를 위한 공정
|
|
BR112018074453A2
(pt)
|
2016-05-27 |
2019-03-19 |
Abbvie Biotherapeutics Inc. |
proteínas de ligação biespecíficas ligando uma protéina imunomoduladora e um antígeno tumoral
|
|
SI3464361T1
(sl)
|
2016-05-27 |
2022-01-31 |
Abbvie Biotherapeutics Inc. |
Protitelesa proti CD40 in njihove uporabe
|
|
EP3468997B1
(en)
|
2016-06-08 |
2023-09-13 |
Xencor, Inc. |
Treatment of igg4-related diseases with anti-cd19 antibodies crossbinding to cd32b
|
|
WO2017211321A1
(zh)
*
|
2016-06-08 |
2017-12-14 |
上海交通大学医学院 |
增强激动型抗体活性的抗体重链恒定区序列
|
|
KR102379464B1
(ko)
|
2016-06-20 |
2022-03-29 |
키맵 리미티드 |
항-pd-l1 항체
|
|
SG11201811431VA
(en)
|
2016-07-14 |
2019-01-30 |
Genmab As |
Multispecific antibodies against cd40 and cd137
|
|
JP7241677B2
(ja)
|
2016-07-19 |
2023-03-17 |
テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド |
抗ｃｄ４７併用療法
|
|
CN109843916B
(zh)
|
2016-08-12 |
2023-10-31 |
詹森生物科技公司 |
具有增强的激动活性的Fc工程化抗TNFR超家族成员抗体及其使用方法
|
|
WO2018031258A1
(en)
|
2016-08-12 |
2018-02-15 |
Janssen Biotech, Inc. |
Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
|
|
CN109790220A
(zh)
|
2016-08-25 |
2019-05-21 |
豪夫迈·罗氏有限公司 |
与巨噬细胞激活剂组合的抗csf-1r抗体的间歇给药
|
|
GB201713765D0
(en)
|
2017-08-28 |
2017-10-11 |
Psioxus Therapeutics Ltd |
Modified adenovirus
|
|
CN119614520A
(zh)
|
2016-08-29 |
2025-03-14 |
阿卡米斯生物公司 |
携带双特异性t细胞衔接器的腺病毒
|
|
CN110546164B
(zh)
|
2016-11-11 |
2023-10-20 |
锦湖Ht株式会社 |
特异性结合cd40的抗体及其用途
|
|
WO2018115003A2
(en)
|
2016-12-19 |
2018-06-28 |
Glenmark Pharmaceuticals S.A. |
Novel tnfr agonists and uses thereof
|
|
CN110072553B
(zh)
|
2016-12-22 |
2023-09-15 |
豪夫迈·罗氏有限公司 |
在抗pd-l1/pd1治疗失败之后抗csf-1r抗体与抗pd-l1抗体组合对肿瘤的治疗
|
|
CN109071656B
(zh)
|
2017-01-05 |
2021-05-18 |
璟尚生物制药公司 |
检查点调节物拮抗剂
|
|
CA3049842A1
(en)
*
|
2017-02-02 |
2018-08-09 |
Silverback Therapeutics, Inc. |
Construct-peptide compositions and methods of use thereof
|
|
KR20250140128A
(ko)
|
2017-02-10 |
2025-09-24 |
젠맵 비. 브이 |
폴리펩티드 변이체 및 그의 용도
|
|
AU2018235928B2
(en)
|
2017-03-14 |
2023-09-21 |
Amgen Inc. |
Control of total afucosylated glycoforms of antibodies produced in cell culture
|
|
US10259865B2
(en)
|
2017-03-15 |
2019-04-16 |
Adma Biologics, Inc. |
Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
|
|
AU2018237683A1
(en)
|
2017-03-24 |
2019-10-31 |
Seagen Inc. |
Process for the preparation of glucuronide drug-linkers and intermediates thereof
|
|
CA3055433A1
(en)
*
|
2017-03-29 |
2018-10-04 |
Glycotope Gmbh |
Humanized anti-cd40 antibodies
|
|
WO2018180914A1
(ja)
|
2017-03-30 |
2018-10-04 |
日油株式会社 |
自壊性アセタールリンカーを有する親水性ポリマー誘導体及びそれを用いた複合体
|
|
EP3604385B1
(en)
|
2017-03-30 |
2024-05-01 |
NOF Corporation |
Heterobifunctional monodispersed polyethylene glycol and conjugate using the same
|
|
AU2018247796A1
(en)
*
|
2017-04-04 |
2019-08-29 |
F. Hoffmann-La Roche Ag |
Novel bispecific antigen binding molecules capable of specific binding to CD40 and to FAP
|
|
KR20190136076A
(ko)
|
2017-04-13 |
2019-12-09 |
에프. 호프만-라 로슈 아게 |
암 치료 방법에 사용하기 위한 인터루킨-2 면역접합체, cd40 작용제 및 임의적인 pd-1 축 결합 길항제
|
|
MX2019014375A
(es)
|
2017-06-01 |
2020-01-23 |
Jiangsu Hengrui Medicine Co |
Anticuerpo anti-cd40, fragmento de union a antigeno del mismo, y uso medico del mismo.
|
|
PL3630143T3
(pl)
*
|
2017-06-01 |
2023-10-30 |
Akamis Bio Limited |
Wirus onkolityczny i sposób
|
|
EP3418302A1
(en)
|
2017-06-19 |
2018-12-26 |
F. Hoffmann-La Roche AG |
Administration routes for immune agonists
|
|
JP2020521788A
(ja)
*
|
2017-06-02 |
2020-07-27 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
免疫アゴニストの投与経路
|
|
CN111032694B
(zh)
|
2017-07-14 |
2024-03-08 |
辉瑞大药厂 |
针对madcam的抗体
|
|
SG11202000198QA
(en)
|
2017-08-04 |
2020-02-27 |
Genmab As |
Binding agents binding to pd-l1 and cd137 and use thereof
|
|
CN111511762B
(zh)
|
2017-08-21 |
2025-05-06 |
天演药业公司 |
抗cd137分子及其用途
|
|
EP3684813B1
(en)
*
|
2017-09-19 |
2025-10-08 |
MAB Discovery GmbH |
Agonistic cd40 antibodies
|
|
US10610585B2
(en)
|
2017-09-26 |
2020-04-07 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and compositions for treating and preventing HIV
|
|
KR102782136B1
(ko)
|
2017-11-08 |
2025-03-18 |
쿄와 기린 가부시키가이샤 |
CD40과 EpCAM에 결합하는 이중특이적 항체
|
|
CN111788227B
(zh)
|
2017-12-27 |
2025-02-25 |
百时美施贵宝公司 |
抗cd40抗体及其用途
|
|
CN109971723B
(zh)
*
|
2017-12-28 |
2023-07-07 |
上海细胞治疗研究院 |
包含CD40抗体与muc1特异性嵌合抗原受体基因的T细胞及其用途
|
|
CN109971717B
(zh)
*
|
2017-12-28 |
2023-06-20 |
上海细胞治疗研究院 |
共表达cd40抗体与间皮素特异性嵌合抗原受体的t细胞及其用途
|
|
US12398209B2
(en)
|
2018-01-22 |
2025-08-26 |
Janssen Biotech, Inc. |
Methods of treating cancers with antagonistic anti-PD-1 antibodies
|
|
GB201801614D0
(en)
|
2018-01-31 |
2018-03-14 |
Psioxus Therapeutics Ltd |
Formulation
|
|
WO2019148444A1
(en)
|
2018-02-02 |
2019-08-08 |
Adagene Inc. |
Anti-ctla4 antibodies and methods of making and using the same
|
|
WO2019148445A1
(en)
|
2018-02-02 |
2019-08-08 |
Adagene Inc. |
Precision/context-dependent activatable antibodies, and methods of making and using the same
|
|
CA3093645A1
(en)
|
2018-03-13 |
2019-09-19 |
Nof Corporation |
Heterobifunctional compound having monodispersed polyethylene glycol in main chain and side chain
|
|
BR112020019559A2
(pt)
|
2018-03-26 |
2021-01-12 |
Amgen Inc. |
Glicoformas afucosiladas totais de anticorpos produzidos em cultura de células
|
|
AU2019246983B2
(en)
|
2018-04-02 |
2025-12-18 |
Amgen Inc. |
Erenumab compositions and uses thereof
|
|
CN112512572B
(zh)
|
2018-04-20 |
2024-12-10 |
礼进生物医药科技（上海）有限公司 |
抗cd40抗体及其用途
|
|
TW202003576A
(zh)
*
|
2018-05-10 |
2020-01-16 |
美商艾博視訊有限公司 |
活化cd40之單株抗體及其用途
|
|
WO2019232533A1
(en)
*
|
2018-06-01 |
2019-12-05 |
Massachusetts Institute Of Technology |
Combination treatments of hsp90 inhibitors for enhancing tumor immunogenicity and methods of use thereof
|
|
CN112638375A
(zh)
|
2018-06-15 |
2021-04-09 |
旗舰创业创新五公司 |
通过后细胞信号传导因子的调节来增加免疫活性
|
|
CN112739717B
(zh)
|
2018-06-29 |
2025-02-11 |
璟尚生物制药公司 |
三特异性拮抗剂
|
|
JP7155403B2
(ja)
|
2018-08-20 |
2022-10-18 |
ファイザー・インク |
抗ｇｄｆ１５抗体、組成物および使用の方法
|
|
EP3847196A4
(en)
|
2018-09-07 |
2023-01-04 |
ITabMed (HK) Limited |
BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
|
|
EP3860653A1
(en)
|
2018-10-05 |
2021-08-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and systems for controlling the agonistic properties of antibody variable domains by light
|
|
EP3939998A4
(en)
|
2018-11-30 |
2022-08-10 |
Jiangsu Hengrui Medicine Co., Ltd. |
PHARMACEUTICAL COMPOSITION WITH CD40 ANTIBODY AND USE THEREOF
|
|
BR112021009835A2
(pt)
|
2018-11-30 |
2021-08-17 |
Jiangsu Hengrui Medicine Co., Ltd. |
anticorpo anti-cd40, fragmento de ligação ao antígeno e uso farmacêutico dos mesmos
|
|
WO2020132810A1
(en)
|
2018-12-24 |
2020-07-02 |
Generon (Shanghai) Corporation Ltd. |
Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof
|
|
CN113677365A
(zh)
*
|
2019-01-22 |
2021-11-19 |
瑞伟生物科技公司(美国) |
新型抗cd40抗体
|
|
US10570210B1
(en)
|
2019-03-04 |
2020-02-25 |
Beijing Mabworks Biotech Co.Ltd |
Antibodies binding CD40 and uses thereof
|
|
EP3947454A1
(en)
|
2019-03-27 |
2022-02-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Recombinant proteins with cd40 activating properties
|
|
WO2020207470A1
(zh)
|
2019-04-10 |
2020-10-15 |
南开大学 |
抗cd40抗体及其用途
|
|
WO2020227159A2
(en)
|
2019-05-03 |
2020-11-12 |
Flagship Pioneering Innovations V, Inc. |
Methods of modulating immune activity
|
|
WO2020230899A1
(ja)
|
2019-05-15 |
2020-11-19 |
協和キリン株式会社 |
Ｃｄ４０とｆａｐに結合するバイスペシフィック抗体
|
|
WO2020230901A1
(ja)
|
2019-05-15 |
2020-11-19 |
協和キリン株式会社 |
Ｃｄ４０とｇｐｃ３に結合するバイスペシフィック抗体
|
|
US10851157B2
(en)
|
2019-07-01 |
2020-12-01 |
Gensun Biopharma, Inc. |
Antagonists targeting the TGF-β pathway
|
|
WO2021048135A1
(en)
|
2019-09-09 |
2021-03-18 |
Basilea Pharmaceutica International AG |
Pharmaceutical combinations comprising a furazanobenzimidazoles and a cd40 agonist for use in the treatment of neoplastic diseases
|
|
US20220362397A1
(en)
|
2019-09-26 |
2022-11-17 |
Nof Corporation |
Heterobifunctional monodispersed polyethylene glycol having peptide linker
|
|
MX2022003461A
(es)
|
2019-09-26 |
2022-04-19 |
Amgen Inc |
Metodos de produccion de composiciones de anticuerpos.
|
|
KR20220109436A
(ko)
*
|
2019-12-03 |
2022-08-04 |
에보텍 인터내셔널 게엠베하 |
인터페론-결합된 항원 결합 단백질 및 이의 용도
|
|
JP2023509359A
(ja)
|
2019-12-17 |
2023-03-08 |
フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド |
鉄依存性細胞分解の誘導物質との併用抗癌療法
|
|
MX2022007688A
(es)
|
2019-12-20 |
2022-07-19 |
Amgen Inc |
Constructos de anticuerpo multiespecificos agonistas de cd40 dirigidos a mesotelina para el tratamiento de tumores solidos.
|
|
WO2021140222A1
(en)
*
|
2020-01-10 |
2021-07-15 |
Symphogen A/S |
Anti-cd40 antibodies and compositions
|
|
IL272194A
(en)
|
2020-01-22 |
2021-07-29 |
Yeda Res & Dev |
Multispecific antibodies for use in treating diseases
|
|
US20230210967A1
(en)
|
2020-04-23 |
2023-07-06 |
Brightpath Biotherapeutics Co., Ltd. |
Improved peptide vaccine
|
|
TW202200622A
(zh)
|
2020-05-13 |
2022-01-01 |
瑞士商天演藥業公司 |
用於治療癌症之組成物及方法
|
|
IL298168A
(en)
|
2020-05-14 |
2023-01-01 |
Molecular Partners Ag |
Multispecific proteins
|
|
US20240279309A1
(en)
|
2020-05-14 |
2024-08-22 |
Molecular Partners Ag |
Recombinant cd40 binding proteins and their use
|
|
WO2021239838A2
(en)
|
2020-05-26 |
2021-12-02 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Severe acute respiratory syndrome coronavirus 2 (sars-cov-2) polypeptides and uses thereof for vaccine purposes
|
|
GB202008003D0
(en)
|
2020-05-28 |
2020-07-15 |
Quine Medical Ab |
Anti-CD40 antibody
|
|
WO2021247892A1
(en)
|
2020-06-04 |
2021-12-09 |
Amgen Inc. |
Assessment of cleaning procedures of a biotherapeutic manufacturing process
|
|
KR20230020521A
(ko)
*
|
2020-06-04 |
2023-02-10 |
셀벡스 피티와이 리미티드 |
아고니스트 항-cd40 항체
|
|
JP2023532339A
(ja)
|
2020-06-29 |
2023-07-27 |
フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド |
サノトランスミッションを促進するためにエンジニアリングされたウイルス及び癌の処置におけるそれらの使用
|
|
CN116234909A
(zh)
*
|
2020-08-21 |
2023-06-06 |
上海药明生物技术有限公司 |
Cd40激动剂抗体和使用方法
|
|
AU2021360897A1
(en)
|
2020-10-15 |
2023-05-25 |
Amgen Inc. |
Relative unpaired glycans in antibody production methods
|
|
CA3200878A1
(en)
|
2020-11-12 |
2022-05-19 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Antibodies conjugated or fused to the receptor-binding domain of the sars-cov-2 spike protein and uses thereof for vaccine purposes
|
|
EP4267176A1
(en)
|
2020-12-23 |
2023-11-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Chlamydia vaccine based on targeting momp vs4 antigen to antigen presenting cells
|
|
WO2022147481A1
(en)
|
2020-12-30 |
2022-07-07 |
Ansun Biopharma Inc. |
Combination therapy of an oncolytic virus delivering a foreign antigen and an engineered immune cell expressing a chimeric receptor targeting the foreign antigen
|
|
CA3204552A1
(en)
*
|
2021-01-08 |
2022-07-14 |
Joseph M. LUETTGEN |
Antibodies and antigen binding peptides for factor xia inhibitors and uses thereof
|
|
US20240173442A1
(en)
|
2021-01-13 |
2024-05-30 |
Hoffmann-La Roche Inc. |
Combination therapy
|
|
CA3209251A1
(en)
|
2021-01-29 |
2022-08-04 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Chlamydia trachomatis antigenic polypeptides and uses thereof for vaccine purposes
|
|
TW202241508A
(zh)
|
2021-01-29 |
2022-11-01 |
美商艾歐凡斯生物治療公司 |
細胞介素相關之腫瘤浸潤性淋巴球組合物及方法
|
|
JP2024511277A
(ja)
|
2021-02-19 |
2024-03-13 |
メビオン・メディカル・システムズ・インコーポレーテッド |
粒子線治療システムのためのガントリー
|
|
KR20230169135A
(ko)
|
2021-03-09 |
2023-12-15 |
젠맵 에이/에스 |
치료에 있어서 cd40 및 cd137에 대한 다중특이 결합제
|
|
JP2024512669A
(ja)
|
2021-03-31 |
2024-03-19 |
フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド |
タノトランスミッションポリペプチド及び癌の処置におけるそれらの使用
|
|
EP4352094A1
(en)
|
2021-06-07 |
2024-04-17 |
Amgen Inc. |
Using fucosidase to control afucosylation level of glycosylated proteins
|
|
BR112023026111A2
(pt)
*
|
2021-06-28 |
2024-03-05 |
Jiangsu Hengrui Pharmaceuticals Co Ltd |
Anticorpo anti-cd40, fragmento de ligação ao antígeno e uso médico do mesmo
|
|
US20240316104A1
(en)
|
2021-06-29 |
2024-09-26 |
Flagship Pioneering Innovations V, Inc. |
Immune cells engineered to promote thanotransmission and uses thereof
|
|
JP2024525758A
(ja)
|
2021-07-13 |
2024-07-12 |
ビオンテック・ソシエタス・エウロパエア |
がんのための併用療法におけるｃｄ４０およびｃｄ１３７に対する多重特異性結合剤
|
|
EP4402174A1
(en)
*
|
2021-09-17 |
2024-07-24 |
Novartis AG |
Methods for prevention of graft rejection in xenotransplantation
|
|
JP2024538573A
(ja)
*
|
2021-10-01 |
2024-10-23 |
マブ ディスカバリー ゲゼルシャフト ミット ベシュレンクテル ハフツング |
免疫刺激剤としてのアゴニスト性ｃｄ４０抗体
|
|
AU2022361382A1
(en)
|
2021-10-05 |
2024-03-28 |
Amgen Inc. |
Fc-gamma receptor ii binding and glycan content
|
|
US12234294B2
(en)
|
2021-11-05 |
2025-02-25 |
Kiniksa Pharmaceuticals, Gmbh |
Pharmaceutical composition of a humanized anti-CD40 antibody
|
|
KR20240103030A
(ko)
|
2021-11-17 |
2024-07-03 |
인스티튜트 내셔날 드 라 싼테 에 드 라 리셰르셰 메디칼르 |
범용 사르베코바이러스 백신
|
|
WO2023147488A1
(en)
|
2022-01-28 |
2023-08-03 |
Iovance Biotherapeutics, Inc. |
Cytokine associated tumor infiltrating lymphocytes compositions and methods
|
|
AU2023231622A1
(en)
*
|
2022-03-07 |
2024-09-26 |
Agenus Inc. |
Anti-ilt2 antibodies and uses thereof
|
|
WO2023193239A1
(en)
|
2022-04-08 |
2023-10-12 |
Peter Peizhi Luo |
Anti-cd28 antibodies and methods of use thereof
|
|
US20250249278A1
(en)
|
2022-04-14 |
2025-08-07 |
Institut National de la Santé et de la Recherche Médicale |
Methods for controlling the tumor cell killing by light
|
|
WO2023215725A1
(en)
|
2022-05-02 |
2023-11-09 |
Fred Hutchinson Cancer Center |
Compositions and methods for cellular immunotherapy
|
|
EP4534559A4
(en)
|
2022-05-31 |
2025-11-05 |
Futuregen Biopharmaceutical Beijing Co Ltd |
Anti-CD40 antibodies, bispecific anti-PD-L1×CD40 antibodies, and their use
|
|
WO2024054992A1
(en)
|
2022-09-09 |
2024-03-14 |
Bristol-Myers Squibb Company |
Methods of separating chelator
|
|
AU2023347072A1
(en)
*
|
2022-09-20 |
2025-01-02 |
Currus Biologics Pty Ltd |
Bispecific polypeptides and uses thereof
|
|
WO2024076969A1
(en)
*
|
2022-10-04 |
2024-04-11 |
Memorial Sloan-Kettering Cancer Center |
Anti-cd40 antibodies and uses thereof
|
|
WO2024077191A1
(en)
|
2022-10-05 |
2024-04-11 |
Flagship Pioneering Innovations V, Inc. |
Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
|
|
WO2024074571A1
(en)
|
2022-10-05 |
2024-04-11 |
Institut National de la Santé et de la Recherche Médicale |
Dc-targeting vaccine against nipah virus infection
|
|
WO2024118836A1
(en)
|
2022-11-30 |
2024-06-06 |
Iovance Biotherapeutics, Inc. |
Processes for production of tumor infiltrating lymphocytes with shortened rep step
|
|
JP2025541738A
(ja)
|
2022-12-01 |
2025-12-23 |
ビオンテック・ソシエタス・エウロパエア |
抗ｐｄ１ａｂと化学療法での併用療法におけるｃｄ４０およびｃｄ１３７に対する多重特異性抗体
|
|
CN115969997B
(zh)
*
|
2022-12-19 |
2024-02-13 |
华润生物医药有限公司 |
一种靶向cldn18.2的抗体药物偶联物及其应用
|
|
CN116375870B
(zh)
*
|
2022-12-30 |
2023-09-15 |
优睿赛思(武汉)生物科技有限公司 |
抗人cd40蛋白的人源化抗体、制备方法及其应用
|
|
WO2024151687A1
(en)
|
2023-01-09 |
2024-07-18 |
Flagship Pioneering Innovations V, Inc. |
Genetic switches and their use in treating cancer
|
|
WO2024213635A1
(en)
*
|
2023-04-12 |
2024-10-17 |
Evotec International Gmbh |
Interferon-associated antigen binding proteins for use for the treatment or prevention of hepatitis delta virus infection
|
|
WO2024220916A1
(en)
|
2023-04-20 |
2024-10-24 |
Amgen Inc. |
Methods of determining relative unpaired glycan content
|
|
WO2025038600A1
(en)
|
2023-08-14 |
2025-02-20 |
Amgen Inc. |
Methods for reducing yellow color
|
|
WO2025250159A2
(en)
*
|
2023-08-24 |
2025-12-04 |
The Trustees Of Columbia University In The City Of New York |
N-linked glycan removal mutant antibodies and their use against influenza viruses
|
|
WO2025101820A1
(en)
|
2023-11-08 |
2025-05-15 |
Fred Hutchinson Cancer Center |
Compositions and methods for cellular immunotherapy
|
|
CN120424223A
(zh)
*
|
2024-02-04 |
2025-08-05 |
苏州泽璟生物制药股份有限公司 |
包含lrrc15抗原结合结构域的多特异性抗体
|
|
WO2025245964A1
(zh)
*
|
2024-05-28 |
2025-12-04 |
中生康元生物科技(北京)有限公司 |
一种树突状细胞制剂及其制备方法
|